Asbestos & Mesothelioma Studies

Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results

Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]

Read More »

Survival Improves in Mesothelioma Patients who Received an Electricity-Based Treatment

The success of a recent Phase II clinical trial in malignant pleural mesothelioma has scientists and researchers excited about the possibility of adding a new treatment that will not only improve survival, but also improve quality of life of the cancer patient. Tumor Treating Fields, which is a therapy that[…]

Read More »

Sarcopenia in Relation to Overall Survival in Peritoneal Mesothelioma

Peritoneal mesothelioma only affects about 500 people each year, but its aggressive nature makes it hard to treat successfully and many who are diagnosed will on average survive only 6 to 12 months. Peritoneal mesothelioma is a cancer affecting the abdominal lining, or peritoneum, which is why it is sometimes referred[…]

Read More »

Empathetic Nurses Have Positive Impact on Cellular Activity in Pleural Mesothelioma Patients

A mesothelioma diagnosis and the treatment involved take a dramatic toll on the body and the mind, and with no known cure for mesothelioma, it is understandable that many feel loss of hope and despair. However, a recent study showed that having good mental health can improve treatment outcome, and[…]

Read More »

Giant Steps Back in the Fight to Ban Asbestos In the United States

Under the Obama Administration, The Toxic Substances Control Act (TSCA) was updated to give the Environmental Protection Agency (EPA) more authority to ban asbestos completely in the United States. The carcinogen was originally banned in 1989, but by 1991 the ruling was over-turned. Anti-asbestos advocates have been fighting ever since[…]

Read More »

New Surgical Technique Illuminates Previously Undetected Mesothelioma Tumors

In addition to chemotherapy, radiation therapy, and immunotherapy, those suffering from mesothelioma also have the option for surgery (if they are physically able). Surgery is one of the better options for mesothelioma patients because it can remove most if not all the cancer; however, often times since the cancer is[…]

Read More »

Metal-based Compound May Reduce Tumor Size in Pleural, Peritoneal Mesothelioma

Mesothelial cells are found in the lining of major organs such as the chest or the abdomen. When asbestos fibers are inhaled or ingested, they slice through the soft tissue and become embedded in the lining of these organs. These fibers cause genetic mutations in the mesothelial cells which then[…]

Read More »

Potential Breakthrough in Immunotherapy after Nivolumab Study Results

Immunotherapy treatments have once again made headlines, revolutionizing modern medicine and the way we have come to understand cancer treatment. The latest study results published in the American Journal of Case Reports, focuses on Opdivo (nivolumab), a type of check point inhibitor designed to stop immune cells from attacking the[…]

Read More »

Pneumothorax Helps Improve CT Scans, Early Detection for Mesothelioma Patients

Diagnosing mesothelioma in the early stages of the disease has proven to be a difficult task, and to better improve chances of survival from this aggressive cancer, the  cancer needs to be found and treated quickly. Typical first steps in diagnosing mesothelioma are imaging techniques such as an x-ray, CT[…]

Read More »

Nintedanib May Surpass Bevacizumab as a More Effective Chemotherapy Treatment for Mesothelioma

In 2016, scientists and researchers were excited to begin Phase II of the clinical trial involving treating patients with malignant pleural mesothelioma with Nintedanib, a triple angiokinase inhibitor designed to hinder protein kinases in cancer cells and stop cancer cells from growing their own blood vessels. The LUME-Meso Phase II[…]

Read More »